Friday, January 28, 2011

BiPar breast cancer drug fails late-stage trial

Genentech's Rituxan wins FDA approval for advanced follicular lymphoma

Fluidigm prices IPO at $13.50 to $15 per share

Success with Genentech cancer drug Tarceva could end study early

Bionovo to raise $30M for R&D

UCSF to hire more San Francisco residents for hospital project

Portola Pharmaceuticals targets antidote to blood thinners

Friday, January 7, 2011

IPierian wants closer ties to 'father' of induced pluripotent stem cells Yamanaka

23andMe snags another $9M in funding

Executive Profile: iPierian CEO Michael Venuti

StemCells lines up $10M stock financing

UCSF, University of Michigan, Cleveland Clinic artificial kidney could knock out dialysis

Avastin, Esbriet drug approvals: Go figure

Pfizer, Sutro cut peptide drug research deal